AtriCure (NASDAQ:ATRC) Hits New 12-Month High – Still a Buy?

16 Sep 2026, 09:01 by Danessa Lincoln · The Markets Daily

AtriCure, Inc. (NASDAQ:ATRC – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $55.94 and last traded at $55.5010, with a volume of 34758 shares changing hands. The stock had previously closed at $54.54.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Weiss Ratings raised shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. UBS Group reduced their target price on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th. Finally, BTIG Research raised their price target on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $52.00.

Get Our Latest Research Report on AtriCure

AtriCure Stock Performance

The firm has a market cap of $2.86 billion, a PE ratio of 267.73 and a beta of 1.26. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The company has a 50-day simple moving average of $43.35 and a two-hundred day simple moving average of $33.91.

AtriCure (NASDAQ:ATRC – Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The firm had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period last year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities research analysts forecast that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Insider Transactions at AtriCure

In related news, insider Vinayak Doraiswamy sold 6,000 shares of AtriCure stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total value of $233,280.00. Following the sale, the insider owned 86,511 shares of the company’s stock, valued at approximately $3,363,547.68. The trade was a 6.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Karl S. Dahlquist sold 9,370 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the transaction, the insider owned 87,319 shares in the company, valued at approximately $4,269,025.91. The trade was a 9.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 70,349 shares of company stock valued at $3,046,757. Corporate insiders own 4.00% of the company’s stock.

Institutional Trading of AtriCure

A number of large investors have recently bought and sold shares of ATRC. Harbor Investment Advisory LLC purchased a new position in shares of AtriCure during the 2nd quarter valued at $40,000. Allworth Financial LP purchased a new stake in AtriCure in the 2nd quarter worth about $43,000. Integrated Wealth Concepts LLC purchased a new stake in AtriCure in the 2nd quarter worth about $46,000. Fifth Third Bancorp bought a new stake in AtriCure in the 1st quarter valued at about $51,000. Finally, Global Retirement Partners LLC bought a new stake in AtriCure in the 2nd quarter valued at about $52,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Company Profile

(Get Free Report)

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.